… Leading Intellectual Property Estate for ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, … US patent No. 11,781,134 that relates to a method for RNA editing. Key claims in this patent pertain to use of any …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
… Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 Platform demonstrates … RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key …
… ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide … ® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR (Adenosine Deaminase Acting on …
